BioSpace News Archive

FDA

FDA Approves Sandoz Biosimilar to Biogen’s MS Therapy Tysabri

Amid one of the industry’s steepest patent cliffs, the regulator Thursday approved Sandoz’s Tyruko, the first biosimilar for treating relapsing multiple sclerosis in adults. Sandoz is a division of Novartis.

August 25, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Exelixis Ends Phase III Trial Early Due to ‘Dramatic’ Benefits in Neuroendocrine Tumors

Following a late-stage victory on Monday, Exelixis on Thursday reported another Phase III win for its tyrosine kinase inhibitor Cabometyx—this time in advanced neuroendocrine tumors.

August 25, 2023
·
2 min read
·
Tristan Manalac
Drug Development

Week in Review: Wegovy’s Cardio Benefits, Biosimilars Gather Momentum and More

A second trial shows Novo Nordisk’s Wegovy improves heart health. Meanwhile, many other drugs are beginning to face generic competition, including from newly approved biosimilars.

August 25, 2023
·
2 min read
·
Greg Slabodkin
Drug Development

Novo Adds Another Cardio Win for Wegovy, Shows Benefits in Heart Failure

Wegovy’s highest dose significantly improved physical function and quality of life in obese patients with heart failure, according to results published Friday in The New England Journal of Medicine.

August 25, 2023
·
2 min read
·
Kate Goodwin
Business

Merck, Eisai Drop Phase III Keytruda-Lenvima Trial for Head and Neck Cancer

While an initial analysis showed improvements in progression-free survival and objective response rate, a second analysis saw no improvement in overall survival.

August 25, 2023
·
2 min read
·
Connor Lynch
Genetown

Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS) today announced that it will present information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy at the upcoming 2023 HAEi Regional EMEA Conference in Munich, Germany from September 1-3, 2023.

August 25, 2023
·
1 min read
Biotech Beach

Biocept to Hold Business Update Conference Call on August 30, 2023

Biocept, Inc. (Nasdaq: BIOC) management will hold a conference call on August 30, 2023, beginning at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) to provide a business update and to answer questions.

August 25, 2023
·
1 min read
Business

Akebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2023 and reviewed recent business highlights.

August 25, 2023
·
19 min read
Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

Ceapro Inc. announced the signing of an amendment to its long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market.

August 25, 2023
·
3 min read
BioMidwest

GE HealthCare Introduces Vscan Air SL, a Wireless Handheld Ultrasound Device for Rapid Assessments of Cardiac and Vascular Patients

GE HealthCare announced the launch of Vscan Air SL – a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions.

August 25, 2023
·
5 min read